Tianhui Chuangtou
VC Fund
Beijing, China
Tianhui Chuangtou is an investment firm that provides asset management and investment consulting service.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Tianhui Chuangtou invests in
Stages Tianhui Chuangtou invests in
Countries Tianhui Chuangtou invests in
Investment Focus
Industry
- Biotechnology 2 (40%)
- Manufacturing 2 (40%)
- Recruiting 1 (20%)
- Outsourcing 1 (20%)
- Therapeutics 1 (20%)
Stage
- Series B 2 (40%)
- Angel 1 (20%)
- Series A 1 (20%)
- Series C 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Baiying Bio offers economic recombinant protein and antibody reagents and is a CRO vendor for life science researchers and biopharma companies. They provide services including HTP recombinant antibody and VHH production, bispecific antibody production, antibody humanization, VHH library generation, hybridoma sequencing, protein expression inmammalian cells, large-scale antibody production, and more. They delivered tens of thousands of recombinant antibodies to customers. | $72.6M / Series B / Aug 31, 2022 | ||
| Bohai New Enzyme is a special enzyme research and development manufacturer. | $125M / Series C / Nov 05, 2021 | ||
| Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a researchand development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million. | $93.8M / Series B / Jun 04, 2021 | ||
Novamab
|
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $15.4M / Series A / Mar 12, 2021 | |
| Souqiantu.com is an intelligent talent management service provider in China. | $425K / Angel / Jan 01, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tianhui Chuangtou invest in?
Tianhui Chuangtou invests primarily in Biotechnology, Manufacturing and Recruiting startups, most often at Series B and Angel stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Tianhui Chuangtou last invest?
The most recent investment recorded for Tianhui Chuangtou closed in Aug 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
